Glucose-Regulated Protein 94 Modulates the Response of Osteosarcoma to Chemotherapy.
Conclusions: Therefore, GRP94 silencing may increase the resistance of MG63 and 143B cells to paclitaxel, gemcitabine, and epirubicin treatments by inhibiting the induction of apoptosis. Thus, GRP94 may be a key biomarker for the chemotherapeutic response of OS.
PMID: 30719181 [PubMed - in process]
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
More News: Bone Cancers | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Chemotherapy | Children | Laboratory Medicine | Osteosarcoma | Study